Latest Bambusa Therapeutics News & Updates

See the latest news and media coverage for Bambusa. We track all announcements, press releases, and industry mentions in real time, all in one place.

Bambusa Therapeutics (Bambusa)

Clinical-stage biotechnology company

Latest news about Bambusa Therapeutics (Bambusa)

May 1 Bambusa

Bambusa completes enrollment in BBT001 trial

The Phase 1b/2a trial targets moderate-to-severe atopic dermatitis. Topline results are expected in mid-2026.
March 17 Bambusa

Bambusa announces Phase I data acceptance for BBT001

Data will be presented as an ePoster at AAD 2026 Annual Meeting. Company highlights rapid execution and best-in-class PK/PD profiles.
January 21 Bambusa

Bambusa announces BBT002 abstract acceptance for ATS 2026 oral presentation

BBT002 targets IL-4Rα and IL-5 for type 2 inflammation. Phase I data from healthy volunteers will be presented.
January 8 Bambusa

Bambusa receives BioSpace NextGen Class of 2026 recognition

It spotlights innovative biotech companies. The team and partners drive this momentum.

April 30 The Manila Times

Bambusa Therapeutics Completes Patient Enrollment in the Phase 1b/2a Trial Evaluating BBT001 as a Treatment for Atopic Dermatitis

Bambusa's lead product candidate, BBT001 is a next-generation long-acting bispecific antibody targeting two clinically and commercially validated targets, IL-4Rα and IL-31 for the treatment of...
April 1 BioSpace

Bambusa Therapeutics Presented Positive Results from the Phase 1 Multiple Ascending Dose Trial of BBT001 at the 2026 American Academy of Dermatology (AAD) Annual Meeting - BioSpace

Immunogenicity: The incidence of ... safety or PK. "We were excited to highlight the data from our BBT001 clinical program for the first time at...
March 19 Morningstar

Bambusa Therapeutics Appoints Todd James Chief Financial Officer

- Mr. James brings more than 20 years of biopharmaceutical leadership experience, with deep expertise in capital markets, investor relations, and corporate strategy, serving in...
January 6 MarketWatch

Bambusa Therapeutics Announces First Patient Dosed in Phase Ib Proof-of-Concept COPD Study of BBT002, Reinforcing Bispecific Pipeline Momentum

"2025 was a year that demonstrated Bambusa's execution-first culture," said Dr. Xu. "With multiple clinical programs advancing in parallel, we are entering 2026 positioned to...

Never miss news about Bambusa

Track Bambusa and your other target companies to get real-time alerts and weekly summaries delivered straight to your inbox.

Browse news for competitors to Bambusa and other trending companies.